Reverse Mergers and SPACs: Are APOs the New Norm for Biotechs Going Public?
Pivot to Cash: Bankruptcy & Restructuring in a Distressed Environment
M&A Outlook 2019
This webinar discussion is focused around best practices in due diligence, potential red flags to avoid, and how working with an experienced team of trusted advisors paired with the right tools can help accelerate the discovery process.
Demystifying Tech M&A Valuation
Maximizing M&A Value, Minimizing Risk: Business Process Integration - Part II
M&A Integration: Maximizing the Return on Technology and Talent
Do's and Don'ts of the M&A Process
M&A Negotiations: Are You As Good As You Could Be?
In this webinar, the most common scenarios that arise when you are selling your company, the choices you have when negotiating the terms of the sale, and which choices are your best ones, as supported by academic research are covered.
The Seven Deadly Sins of Selling Your Tech Company
Intricacies of Cross-Border M&A
In this webinar you will learn what COVID-19 means for today’s cross-border deals, current deal landscape, pre-deal considerations, effects on negotiation of pricing and valuation, deal execution logistics, considerations for deal professionals working remotely, managing corporate and tax issues, and tools to streamline transactions, reduce risks, and increase efficiency.
Must-Know Finance Concepts for Life Sciences Valuations - Part II
This webinar discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.
Understanding Representations and Warranties Insurance in M&A